Crinetics Pharmaceuticals (CRNX) director sells 5,000 shares in planned trade

Q: What did Crinetics Pharmaceuticals (CRNX) director Rogerio Vivaldi Coelho report on this Form 4?

He reported open-market sales of 5,000 shares of Crinetics Pharmaceuticals common stock. The transactions were split into two trades on March 12, 2026, and were executed under a pre-arranged Rule 10b5-1 trading plan .

Q: How many CRNX shares did the director sell and at what prices?

He sold 4,477 shares at a volume-weighted average price of $36.08 and 523 shares at a volume-weighted average price of $36.77 . The filing also discloses specific intraday price ranges for each trade.

Q: What price ranges were involved in the director’s CRNX stock sales?

For the 4,477-share sale, the price range was $35.65 to $36.53 . For the 523-share sale, the range was $36.69 to $36.89 . The filing notes detailed trade breakdowns are available from the company upon request.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Crinetics Pharmaceuticals director Rogerio Vivaldi Coelho sold 5,000 shares of Common Stock in open-market transactions. The sales occurred on March 12, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025, meaning the trades were scheduled in advance.

The transactions comprised 4,477 shares at a volume-weighted average price of $36.08 and 523 shares at a volume-weighted average price of $36.77, within disclosed intraday price ranges. Following these sales, he directly held 16,300 shares of Crinetics Pharmaceuticals common stock.

Insider Trade Summary 10b5-1

Net Seller: 5,000 shares

Net Sell 2 txns

Insider Vivaldi Coelho Rogerio

Role Director

Sold 5,000 shs ($181K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,477	$36.08	$162K
Sale	Common Stock	523	$36.77	$19K

Holdings After Transaction: Common Stock — 16,300 shares (Direct)

Footnotes (3)

F1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.
F2. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $36.08 per share. The range of sales prices on the transaction date was $35.65 to $36.53 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
F3. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $36.77 per share. The range of sales prices on the transaction date was $36.69 to $36.89 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/13/2026 - 05:46 PM

FAQ

What did Crinetics Pharmaceuticals (CRNX) director Rogerio Vivaldi Coelho report on this Form 4?

He reported open-market sales of 5,000 shares of Crinetics Pharmaceuticals common stock. The transactions were split into two trades on March 12, 2026, and were executed under a pre-arranged Rule 10b5-1 trading plan.

How many CRNX shares did the director sell and at what prices?

He sold 4,477 shares at a volume-weighted average price of $36.08 and 523 shares at a volume-weighted average price of $36.77. The filing also discloses specific intraday price ranges for each trade.

How many Crinetics Pharmaceuticals (CRNX) shares does the director hold after these transactions?

After the reported sales, Rogerio Vivaldi Coelho directly holds 16,300 shares of Crinetics Pharmaceuticals common stock. This post-transaction holding figure comes directly from the Form 4’s ownership information for his non-derivative common stock position.

Were the CRNX stock sales by the director pre-planned under a Rule 10b5-1 plan?

Yes. A footnote states the sales were executed automatically under a Rule 10b5-1 trading plan adopted on December 11, 2025. Such plans schedule trades in advance, reducing the significance of short-term market timing.

What price ranges were involved in the director’s CRNX stock sales?

For the 4,477-share sale, the price range was $35.65 to $36.53. For the 523-share sale, the range was $36.69 to $36.89. The filing notes detailed trade breakdowns are available from the company upon request.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vivaldi Coelho Rogerio

(Last)

(First)

(Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/12/2026		S⁽¹⁾		4,477	D	$36.08⁽²⁾	16,823	D
Common Stock	03/12/2026		S⁽¹⁾		523	D	$36.77⁽³⁾	16,300	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.

2. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $36.08 per share. The range of sales prices on the transaction date was $35.65 to $36.53 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

3. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $36.77 per share. The range of sales prices on the transaction date was $36.69 to $36.89 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

Remarks:

	/s/ Tobin Schilke, as attorney-in-fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR